Skip to main content

Table 5 Survival of pancreatic cancer patients treated with tomotherapy and concurrent capecitabine

From: Helical tomotherapy with concurrent capecitabine for the treatment of inoperable pancreatic cancer

Group Characteristics Median duration of survival (months)
I Locally advanced without metastasis (n = 10) 9.25 (2.00-18.4)
     No previous chemotherapy (n = 8) 12.55 (6.50-18.4)
     Previous chemotherapy (n = 2) 3.90 (2.00, 5.8)
II Locally relapsed without metastasis following complete resection (n = 1) 4.80 (4.80)
III Metastatic disease (n = 8) 4.25 (1.10-21.00)
     De novo (n = 3) 4.40 (3.90-6.50)
     Relapsed (n = 5) 4.10 (1.10-21.00)
  1. Data in parentheses are ranges of survival times